India's Pharma Sector Sees 7.8% Growth in April 2025; Accounts for 20% of Global Generic Supply

India’s pharmaceutical industry continues to expand rapidly, playing a crucial role both in the domestic healthcare landscape and on the global stage. According to a recent press release by the Department of Pharmaceuticals, the sector witnessed a 7.8% year-on-year revenue increase in April 2025, underscoring its resilient growth trajectory. With focused government initiatives and a strong manufacturing base, India is positioning itself as a leading provider of affordable, high-quality healthcare solutions.

India’s Expanding Global Role

India now ranks third globally in pharmaceutical volume and fourteenth in value, supplying 20% of the world’s generic medicines. The country plays a vital part in the global vaccine supply chain, meeting 55–60% of UNICEF’s vaccine demand and a significant portion of the World Health Organisation’s requirements. It is also a key contributor to DPT, BCG, and measles vaccines in markets across Africa, Asia, and the Americas.

Government Schemes Powering Domestic Growth

Flagship programmes such as the Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP) and the Production Linked Incentive (PLI) Scheme are transforming domestic pharmaceutical manufacturing. With over 15,000 Jan Aushadhi Kendras and price reductions up to 80%, PMBJP is improving access to affordable medicines. The PLI Schemes, with budgets totalling over ₹25,000 crore, support advanced drug development, raw material production, and critical medical device manufacturing, while Bulk Drug Parks and SPI schemes enhance R&D and infrastructure.

Read More: Best Pharma Stocks in May 2025 – Based on 5-Yr CAGR

Conclusion

As India enters the Amrit Kaal period, the pharmaceutical industry stands not only as a pillar of economic growth but also as a national lifeline. With continued investment, policy support, and global partnerships, the sector reinforces India’s vision of healthcare equity. The Department’s declaration captures this ambition aptly: “The future of healthcare is here and it’s proudly Indian.”
 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their research and assessments to form an independent opinion about investment decisions.